{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:55:09Z","timestamp":1794264909078,"version":"4.9.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T00:00:00Z","timestamp":1569542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T00:00:00Z","timestamp":1569542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AIRC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Premature ovarian failure and infertility are adverse effects of cancer therapies. The mechanism underlying chemotherapy-mediated depletion of the ovarian reserve remains unclear. Here, we aim to identify the signaling pathways involved in the loss of the ovarian reserve to prevent the damaging effects of chemotherapy. We evaluated the effects of cyclophosphamide, one of the most damaging chemotherapeutic drugs, against follicle reserve. In vivo studies showed that the cyclophosphamide-induced loss of ovarian reserve occurred through a sequential mechanism. Cyclophosphamide exposure induced the activation of both DNAPK-\u03b3H2AX-checkpoint kinase 2 (CHK2)-p53\/TAp63\u03b1 isoform and protein kinase B (AKT)-forkhead box O3 (FOXO3a) signaling axes in the nucleus of oocytes. Concomitant administration of an allosteric ABL inhibitor and cyclophosphamide modulated both pathways while protecting the ovarian reserve from chemotherapy assaults. As a consequence, the fertility of the treated mice was prolonged. On the contrary, the administration of an allosteric ABL activator enhanced the lethal effects of cyclophosphamide while shortening mouse fertility. Therefore, kinase-independent inhibition may serve as an effective ovarian-protective strategy in women under chemotherapy.<\/jats:p>","DOI":"10.1038\/s41419-019-1961-y","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T10:05:04Z","timestamp":1569578704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Kinase-independent inhibition of cyclophosphamide-induced pathways protects the ovarian reserve and prolongs fertility"],"prefix":"10.1038","volume":"10","author":[{"given":"Giovanna","family":"Bellusci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mattiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Iannizzotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ciccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Maiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Villani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Diederich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Gonfloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,27]]},"reference":[{"key":"1961_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/humupd\/dms022","volume":"18","author":"S Morgan","year":"2012","unstructured":"Morgan, S., Anderson, R. A., Gourley, C., Wallace, W. H. & Spears, N. How do chemotherapeutic agents damage the ovary? Hum. Reprod. Update 18, 525\u2013535 (2012).","journal-title":"Hum. Reprod. Update"},{"key":"1961_CR2","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1002\/cncr.23071","volume":"110","author":"O Oktem","year":"2007","unstructured":"Oktem, O. & Oktay, K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 110, 2222\u20132229 (2007).","journal-title":"Cancer"},{"key":"1961_CR3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/GRF.0b013e3181f96b54","volume":"53","author":"D Meirow","year":"2010","unstructured":"Meirow, D., Biederman, H., Anderson, R. A. & Wallace, W. H. Toxicity of chemotherapy and radiation on female reproduction. Clin. Obstet. Gynecol. 53, 727\u2013739 (2010).","journal-title":"Clin. Obstet. Gynecol."},{"key":"1961_CR4","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nature05337","volume":"444","author":"EK Suh","year":"2006","unstructured":"Suh, E. K. et al. p63 protects the female germ line during meiotic arrest. Nature 444, 624\u2013628 (2006).","journal-title":"Nature"},{"key":"1961_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1530\/REP-07-0054","volume":"135","author":"G Livera","year":"2008","unstructured":"Livera, G. et al. p63 null mutation protects mouse oocytes from radio-induced apoptosis. Reproduction 135, 3\u201312 (2008).","journal-title":"Reproduction"},{"key":"1961_CR6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.cell.2011.01.013","volume":"144","author":"GB Deutsch","year":"2011","unstructured":"Deutsch, G. B. et al. DNA damage in oocytes induces a switch of the quality control factor TAp63alpha from dimer to tetramer. Cell 144, 566\u2013576 (2011).","journal-title":"Cell"},{"key":"1961_CR7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.molcel.2012.08.017","volume":"48","author":"JB Kerr","year":"2012","unstructured":"Kerr, J. B. et al. DNA damage-induced primordial follicle oocyte apoptosis and loss of fertility require TAp63-mediated induction of Puma and Noxa. Mol. cell 48, 343\u2013352 (2012).","journal-title":"Mol. cell"},{"key":"1961_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1126\/science.1247671","volume":"343","author":"E Bolcun-Filas","year":"2014","unstructured":"Bolcun-Filas, E., Rinaldi, V. D., White, M. E. & Schimenti, J. C. Reversal of female infertility by Chk2 ablation reveals the oocyte DNA damage checkpoint pathway. Science 343, 533\u2013536 (2014).","journal-title":"Science"},{"key":"1961_CR9","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1534\/genetics.117.203455","volume":"206","author":"VD Rinaldi","year":"2017","unstructured":"Rinaldi, V. D., Hsieh, K., Munroe, R., Bolcun-Filas, E. & Schimenti, J. C. Pharmacological inhibition of the DNA damage checkpoint prevents radiation-induced oocyte death. Genetics 206, 1823\u20131828 (2017).","journal-title":"Genetics"},{"key":"1961_CR10","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41418-018-0151-2","volume":"26","author":"SY Kim","year":"2018","unstructured":"Kim, S. Y. et al. Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ 26, 502\u2013515 (2018).","journal-title":"Cell Death Differ"},{"key":"1961_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41594-018-0035-7","volume":"25","author":"M Tuppi","year":"2018","unstructured":"Tuppi, M. et al. Oocyte DNA damage quality control requires consecutive interplay of CHK2 and CK1 to activate p63. Nat. Struct. Mol. Biol. 25, 261\u2013269 (2018).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1961_CR12","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.2217\/fon-2016-0176","volume":"12","author":"G Bedoschi","year":"2016","unstructured":"Bedoschi, G., Navarro, P. A. & Oktay, K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncol. 12, 2333\u20132344 (2016).","journal-title":"Future Oncol."},{"key":"1961_CR13","doi-asserted-by":"publisher","first-page":"185ra162","DOI":"10.1126\/scitranslmed.3005402","volume":"5","author":"L Kalich-Philosoph","year":"2013","unstructured":"Kalich-Philosoph, L. et al. Cyclophosphamide triggers follicle activation and \u201cBurnout\u201d; AS101 prevents follicle loss and preserves fertility. Sci. Transl. Med 5, 185ra162 (2013).","journal-title":"Sci. Transl. Med"},{"key":"1961_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/17446651.2018.1455498","volume":"13","author":"YL Jayasinghe","year":"2018","unstructured":"Jayasinghe, Y. L., Wallace, W. H. B. & Anderson, R. A. Ovarian function, fertility and reproductive lifespan in cancer patients. Expert Rev. Endocrinol. Metab. 13, 125\u2013136 (2018).","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"1961_CR15","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2016.27.e22","volume":"27","author":"SY Kim","year":"2016","unstructured":"Kim, S. Y., Kim, S. K., Lee, J. R. & Woodruff, T. K. Toward precision medicine for preserving fertility in cancer patients: existing and emerging fertility preservation options for women. J. Gynecol. Oncol. 27, e22 (2016).","journal-title":"J. Gynecol. Oncol."},{"key":"1961_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.fertnstert.2015.11.043","volume":"105","author":"H Roness","year":"2016","unstructured":"Roness, H., Kashi, O. & Meirow, D. Prevention of chemotherapy-induced ovarian damage. Fertil. Steril. 105, 20\u201329 (2016).","journal-title":"Fertil. Steril."},{"key":"1961_CR17","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/nm1009-1124","volume":"15","author":"TK Woodruff","year":"2009","unstructured":"Woodruff, T. K. Preserving fertility during cancer treatment. Nat. Med 15, 1124\u20131125 (2009).","journal-title":"Nat. Med"},{"key":"1961_CR18","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s10815-018-1180-y","volume":"35","author":"JS Shah","year":"2018","unstructured":"Shah, J. S. et al. Biomechanics and mechanical signaling in the ovary: a systematic review. J. Assist Reprod. Genet 35, 1135\u20131148 (2018).","journal-title":"J. Assist Reprod. Genet"},{"key":"1961_CR19","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/nm.2033","volume":"15","author":"S Gonfloni","year":"2009","unstructured":"Gonfloni, S. et al. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat. Med. 15, 1179\u20131185 (2009).","journal-title":"Nat. Med."},{"issue":"8","key":"1961_CR20","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/cdd.2013.31","volume":"20","author":"S-Y Kim","year":"2013","unstructured":"Kim, S. Y. et al. Rescue of platinum-damaged oocytes from programmed cell death through inactivation of the p53 family signaling network. Cell Death Differ. 20, 987\u2013997 (2013).","journal-title":"Cell Death & Differentiation"},{"key":"1961_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070117","volume":"8","author":"S Morgan","year":"2013","unstructured":"Morgan, S., Lopes, F., Gourley, C., Anderson, R. A. & Spears, N. Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatin. PLoS ONE 8, e70117 (2013).","journal-title":"PLoS ONE"},{"key":"1961_CR22","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nm.2852","volume":"18","author":"E Maiani","year":"2012","unstructured":"Maiani, E. et al. Reply to: cisplatin-induced primordial follicle oocyte killing and loss of fertility are not prevented by imatinib. Nat. Med 18, 1172\u20131174 (2012).","journal-title":"Nat. Med"},{"key":"1961_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.chembiol.2010.12.013","volume":"18","author":"J Yang","year":"2011","unstructured":"Yang, J. et al. Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site. Chem. Biol. 18, 177\u2013186 (2011).","journal-title":"Chem. Biol."},{"key":"1961_CR24","first-page":"139","volume":"295","author":"E Buchdunger","year":"2000","unstructured":"Buchdunger, E. et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharm. Exp. Ther. 295, 139\u2013145 (2000).","journal-title":"J. Pharm. Exp. Ther."},{"key":"1961_CR25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00280-011-1662-4","volume":"69","author":"M Tavecchio","year":"2012","unstructured":"Tavecchio, M., Munck, J. M., Cano, C., Newell, D. R. & Curtin, N. J. Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination. Cancer Chemother. Pharm. 69, 155\u2013164 (2012).","journal-title":"Cancer Chemother. Pharm."},{"key":"1961_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nchembio760","volume":"2","author":"FJ Adrian","year":"2006","unstructured":"Adrian, F. J. et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat. Chem. Biol. 2, 95\u2013102 (2006).","journal-title":"Nat. Chem. Biol."},{"key":"1961_CR27","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3389\/fgene.2014.00392","volume":"5","author":"S Gonfloni","year":"2014","unstructured":"Gonfloni, S. Defying c-Abl signaling circuits through small allosteric compounds. Front Genet 5, 392 (2014).","journal-title":"Front Genet"},{"key":"1961_CR28","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.bcp.2011.07.001","volume":"82","author":"E Maiani","year":"2011","unstructured":"Maiani, E., Diederich, M. & Gonfloni, S. DNA damage response: the emerging role of c-Abl as a regulatory switch? Biochemical Pharmacol. 82, 1269\u20131276 (2011).","journal-title":"Biochemical Pharmacol."},{"key":"1961_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0633-7","volume":"9","author":"QN Nguyen","year":"2018","unstructured":"Nguyen, Q. N. et al. Loss of PUMA protects the ovarian reserve during DNA-damaging chemotherapy and preserves fertility. Cell Death Dis. 9, 618 (2018).","journal-title":"Cell Death Dis."},{"issue":"15","key":"1961_CR30","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1007\/s00018-018-2833-9","volume":"75","author":"Jessica M. Stringer","year":"2018","unstructured":"Stringer, J. M., Winship, A., Liew, S. H. & Hutt, K. The capacity of oocytes for DNA repair. Cell Mol. Life Sci. https:\/\/doi.org\/10.1007\/s00018-018-2833-9 (2018).","journal-title":"Cellular and Molecular Life Sciences"},{"key":"1961_CR31","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie, A. A. et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature 543, 733\u2013737 (2017).","journal-title":"Nature"},{"key":"1961_CR32","doi-asserted-by":"crossref","unstructured":"Schoepfer, J. et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J. Med. Chem. 61, 8120\u20138135 (2018).","DOI":"10.1021\/acs.jmedchem.8b01040"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1961-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1961-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1961-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T12:38:15Z","timestamp":1671194295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1961-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,27]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10]]}},"alternative-id":["1961"],"URL":"https:\/\/doi.org\/10.1038\/s41419-019-1961-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/526103","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,27]]},"assertion":[{"value":"4 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"726"}}